Reglodi D, Kiss P, Lubics A, et al. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des 2011; 17: 962–972
Reglodi D, Kiss P, Szabadfi K, et al. PACAP is an endogenous protective factor – insights from PACAP-deficient mice. J Mol Neurosci 2012; 48: 482–492
Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 2010; 9: 237–248
Buxbaum JN, Linke RP. A molecular history of the amyloidoses. J Mol Biol 2012; 421: 142–159
Lavatelli F, Perlman DH, Spencer B, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008; 7: 1570–1583
Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 2017; 86: 27–68
Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898–909
Higuchi K, Naiki H, Kitagawa K, et al. Mouse senile amyloidosis. ASSAM amyloidosis in mice presents universally as a systemic age-associated amyloidosis. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 60: 231–238
Cui D, Hoshii Y, Takahashi M, et al. An immunohistochemical study of amyloid P component, apolipoprotein E and ubiquitin in human and murine amyloidoses. Pathol Int 1998; 48: 362–367
Dogan A. Amyloidosis: insights from proteomics. Annu Rev Pathol 2017; 12: 277–304
Noda S, So M, Adachi M, et al. Thioflavin T-silent denaturation intermediates support the main-chain-dominated architecture of amyloid fibrils. Biochemistry 2016; 55: 3937–3948
Martin EB, Williams A, Richey T, et al. Comparative evaluation of p5 + 14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis. Sci Rep 2016; 6: 22695
Kisilevsky R, Fraser PE. A beta amyloidogenesis: unique, or variation on a systemic theme? Crit Rev Biochem Mol Biol 1997; 32: 361–404
Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today 2015; 20: 122–128
Brahmachari S, Paul A, Segal D, et al. Inhibition of amyloid oligomerization into different supramolecular architectures by small molecules: mechanistic insights and design rules. Future Med Chem 2017; 9: 797–810
Ogren SO, Kuteeva E, Elvander-Tottie E, et al. Neuropeptides in learning and memory processes with focus on galanin. Eur J Pharmacol 2010; 626: 9–17
Somogyvari-Vigh A, Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 2004; 10: 2861–2889
Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009; 61: 283–357
Reglodi D, Tamas A (Eds). Pituitary Adenylate Cyclase Activating Polypeptide – PACAP. Current Topics in Neurotoxicity, Vol 11. Springer Nature: New York, 2016
Abad C, Waschek JA. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. Curr Pharm Des 2011; 17: 1025–1035
Seaborn T, Masmoudi-Kouli O, Fournier A, et al. Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. Curr Pharm Des 2011; 17: 204–214
Han P, Caselli RJ, Baxter L, et al. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease. JAMA Neurol 2015; 72: 333–339
Han P, Nielsen M, Song M, et al. The impact of aging on brain pituitary adenylate cyclase activating polypeptide, pathology and cognition in mice and rhesus macaques. Front Aging Neurosci 2017; 9: 180
Banki E, Sosnowska D, Tucsek Z, et al. Age-related decline of autocrine pituitary adenylate cyclase-activating polypeptide impairs angiogenic capacity of rat cerebromicrovascular endothelial cells. J Gerontol A Biol Sci Med Sci 2015; 70: 665–674
Tripathy D, Sanchez A, Yin X, et al. Age-related decrease in cerebrovascular-derived neuroprotective proteins: effect of acetaminophen. Microvasc Res 2012; 84: 278–285
Ohtaki H, Satoh A, Nakamachi T, et al. Regulation of oxidative stress by pituitary adenylate cyclase-activating polypeptide (PACAP) mediated by PACAP receptor. J Mol Neurosci 2010; 42: 397–403
Kovacs-Valasek A, Szabadfi K, Denes V, et al. Accelerated retinal aging in PACAP knock-out mice. Neuroscience 2017; 348: 1–10
Maasz G, Pirger Z, Reglodi D, et al. Comparative protein composition of the brains of PACAP-deficient mice using mass spectrometry-based proteomic analysis. J Mol Neurosci 2014; 54: 310–319
Hashimoto H, Shintani N, Tanaka K, et al. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci U S A 2001; 98: 13355–13360
Farkas J, Kovacs L, Gaspar L, et al. Construct and face validity of a new model for the three-hit theory of depression using PACAP mutant mice on CD1 background. Neuroscience 2017; 354: 11–29
Linke RP. Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence. Virchows Arch 2000; 436: 439–448
Seymour JF, Lieschke GJ, Grail D, et al. Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. Blood 1997; 90: 3037–3049
Li L, Sawashita J, Ding X, et al. Caloric restriction reduces the systemic progression of mouse AApoAII amyloidosis. PLoS One 2017; 12: e0172402
Longuespee R, Alberts D, Pottier C, et al. A laser microdissection-based workflow for FFPE tissue microproteomics: important considerations for small sample processing. Methods 2016; 104: 154–162
Herfs M, Longuespee R, Quick CM, et al. Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. J Pathol 2017; 241: 522–533
Longuespée R, Casadonte R, Kriegsmann M, et al. Proteomic investigation of human cystic echinococcosis in the liver. Mol Biochem Parasitol 2017; 211: 9–14
Longuespee R, Baiwir D, Mazzucchelli G, et al. Laser microdissection-based microproteomics of formalin-fixed and paraffin-embedded (FFPE) tissues. Methods Mol Biol 2018; 1723: 19–31
Buxbaum JN. Animal models of human amyloidoses: are transgenic mice worth the time and trouble? FEBS Lett 2009; 583: 2663–2673
Higuchi K, Matsumura A, Honma A, et al. Systemic senile amyloid in senescence-accelerated mice. A unique fibril protein demonstrated in tissues from various organs by the unlabeled immunoperoxidase method. Lab Invest 1983; 48: 231–240
Majeed SK. Survey on spontaneous systemic amyloidosis in aging mice. Arzneimittelforschung 1993; 43: 170–178
Takeshita S, Hosokawa M, Irino M, et al. Spontaneous age-associated amyloidosis in senescence-accelerated mouse (SAM). Mech Ageing Dev 1982; 20: 13–23
Perfetto F, Moggi-Pignone A, Livi R, et al. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol 2010; 6: 417–429
Brayton C, Fox JG, Barthold SW, et al. Spontaneous diseases in commonly used mouse strains. In The Mouse in Biomedical Research. Academic Press, New York, USA, 2006; 623–717
Wang Y, Sawashita J, Qian J, et al. ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis. J Lipid Res 2011; 52: 1461–1470
Woldemeskel M. A concise review of amyloidosis in animals. Vet Med Int 2012; 2012: 427296
Bergstrom J, Murphy CL, Weiss DT, et al. Two different types of amyloid deposits – apolipoprotein A-IV and transthyretin – in a patient with systemic amyloidosis. Lab Invest 2004; 84: 981–988
Tashiro F, Yi S, Wakasugi S, et al. Role of serum amyloid P component for systemic amyloidosis in transgenic mice carrying human mutant transthyretin gene. Gerontology 1991; 37(suppl 1): 56–62
Dasari S, Amin MS, Kurtin PJ, et al. Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. Kidney Int 2016; 90: 658–664
Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119: 1844–1847
Obici L, Nuvolone M, Merlini G. Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney. Kidney Int 2016; 90: 479–481
Solomon A, Murphy CL, Kestler D, et al. Amyloid contained in the knee joint meniscus is formed from apolipoprotein A-I. Arthritis Rheum 2006; 54: 3545–3550
Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957–4959
Mollee P, Boros S, Loo D, et al. Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Clin Proteomics 2016; 13: 30
Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5: 2180–2187
Sethi S, Vrana JA, Theis JD, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 2012; 82: 226–234
Casadonte R, Kriegsmann M, Deininger SO, et al. Imaging mass spectrometry analysis of renal amyloidosis biopsies reveals protein co-localization with amyloid deposits. Anal Bioanal Chem 2015; 407: 5323–5331
Kohan AB, Wang F, Lo CM, et al. ApoA-IV: current and emerging roles in intestinal lipid metabolism, glucose homeostasis, and satiety. Am J Physiol Gastrointest Liver Physiol 2015; 308: G472–G481
Kindy MS, Rader DJ. Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. Am J Pathol 1998; 152: 1387–1395
Kindy MS, King AR, Perry G, et al. Association of apolipoprotein E with murine amyloid A protein amyloid. Lab Invest 1995; 73: 469–475
Yamada T, Someya T, Fujita S. Immunotargeting of apolipoprotein E in amyloid: an initial trial in mice. Ann Clin Lab Sci 2009; 39: 134–137
Arciello A, Piccoli R, Monti DM. Apolipoprotein A-I: the dual face of a protein. FEBS Lett 2016; 590: 4171–4179
Gaffney PM, Imai DM, Clifford DL, et al. Proteomic analysis of highly prevalent amyloid A amyloidosis endemic to endangered island foxes. PLoS One 2014; 9: e113765
Qian J, Yan J, Ge F, et al. Mouse senile amyloid fibrils deposited in skeletal muscle exhibit amyloidosis-enhancing activity. PLoS Pathog 2010; 6: e1000914
Usui I, Kawano H, Ito S, et al. Homozygous serum amyloid P component-deficiency does not enhance regression of AA amyloid deposits. Amyloid 2001; 8: 101–104
Ozawa D, Nomura R, Mangione PP, et al. Antiamyloidogenic and proamyloidogenic chaperone effects of C-reactive protein and serum amyloid P component. Amyloid 2017; 24: 28–29
Botto M, Hawkins PN, Bickerstaff MC, et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 1997; 3: 855–859
Togashi S, Lim SK, Kawano H, et al. Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 1997; 77: 525–531
Watson MB, Nobuta H, Abad C, et al. PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice. Neuroscience 2013; 240: 277–286
Ohtaki H, Nakamachi T, Dohi K, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc Natl Acad Sci U S A 2006; 103:7488–7493
Stroo E, Koopman M, Nollen EA, et al. Cellular regulation of amyloid formation in aging and disease. Front Neurosci 2017; 11: 64
Reglodi D, Helyes Z, Nemeth J, et al. PACAP as a potential biomarker – alterations of PACAP levels in human physiological and pathological conditions. In Pituitary Adenylate Cyclase Activating Polypeptide – PACAP. Current Topics in Neurotoxicity, Reglodi D, Tamas A (eds), Vol 11. Springer Nature: New York, 2016; Ch 48, 815–832
Han P, Liang W, Baxter LC, et al. Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease. Neurology 2014; 82: 1724–1728
Han P, Tang Z, Yin J, et al. Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity. Neurobiol Aging 2014; 35: 2064–2071
Takeda T, Matsushita T, Kurozumi M, et al. Pathobiology of the senescence-accelerated mouse (SAM). Exp Gerontol 1997; 32: 117–127
Vaudry D, Hamelink C, Damadzic R, et al. Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult. Peptides 2005; 26: 2518–2524
Szabadfi K, Atlasz T, Kiss P, et al. Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox Res 2012; 21: 41–48
Sukhanova A, Poly S, Shemetov A, et al. Implications of protein structure instability: from physiological to pathological secondary structure. Biopolymers 2012; 97: 577–588
Teng MH, Yin JY, Vidal R, et al. Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest 2001; 81: 385–396
Kojro E, Postina R, Buro C, et al. The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J 2006; 20: 512–514
Postina R. Activation of α-secretase cleavage. J Neurochem 2012; 120(suppl 1): 46–54
Onoue S, Endo K, Ohshima K, et al. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides 2002; 23: 1471–1478
Chang YT, Wong CK, Chow KC, et al. Apoptosis in primary cutaneous amyloidosis. Br J Dermatol 1999; 140: 210–215
Potter KJ, Scrocchi LA, Warnock GL, et al. Amyloid inhibitors enhance survival of cultured human islets. Biochim Biophys Acta 2009; 1790: 566–574
Neree AT, Nguyen PT, Bourgault S. Cell-penetrating ability of peptide hormones: key role of glycosaminoglycans clustering. Int J Mol Sci 2015; 16: 27391–27400
Chatenet D, Fournier A, Bourgault S. PACAP-derived carriers: mechanisms and applications. In Pituitary Adenylate Cyclase Activating Polypeptide – PACAP. Current Topics in Neurotoxicity, Reglodi D, Tamas A (eds), Vol 11. Springer Nature: New York, 2016; Ch 9, 133–148
Nishitsuji K, Uchimura K. Sulfated glycosaminoglycans in protein aggregation diseases. Glycoconj J 2017; 34: 453–466
Marin-Argany M, Lin Y, Misra P, et al. Cell damage in light chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding. J Biol Chem 2016; 291: 19813–19825
